A+ R A-

Genetic Basis and Pathogenesis of WM and IgM Related Disorders

Please select from the following list of abstracts, representing the presentations given in Stockholm 2008 (IWWM-5) Session 2:

Origins of Waldenström’s macroglobulinemia. Linda M. Pilarski, Sophia Adamia, Amanda Reichert, Julia Kirshner, Steven P. Treon, Tony Reiman, Andrew R. Belch Dept. Oncology, University of Alberta and Cross Cancer Institute, CANADA.

CD27 in defining B-cell memory origins in WM. Surinder S. Sahota, Gavin Babbage, Nicola Weston, Bell Cancer Sciences Division, School of Medicine, University of Southampton, Southampton, UNITED KINGDOM.

Cytogenetic abnormalities in a cohort of 120 untreated patients enrolled in the WM1 trial. Trisomy 4 prevalence. F. Nguyen-Khac, Unite de Cytogenetique Hematologique, Service d'Hematologie Biologique, Groupe Hospitalier Pitie-Salpetriere, Pavillon Laveran, 47-83 Bd de l'Hopital, 75013 Paris, FRANCE.

Cytogenetic aberrations in polyneuropathy associated with IgM monoclonal gammopathy. Eurelings M, Lokhorst HM, Notermans NC, Krijtenburg PJ, Kessel B, Eleveld MJ, Bloem A, Wokke JH, Poot M, Buijs A, NETHERLANDS.

NF-kB abnormalities in Waldenström’s Macroglobulinemia. Esteban Braggio, PhD.,  Rafael Fonseca, MD, Mayo Clinic, Scottsdale, AZ, USA.

Immunoglobulin Gene Rearrangements in Waldenström’s macroglobulinemia. Ramón García-Sanz, Patricia Martín-Jiménez, Enrique M. Ocio, María E. Sarasquete, Marcos Gonzalez, Jesus F. San Miguel. Hematology Department. University Hospital of Salamanca, SPAIN.

High-throughput microRNA profiling: Identification of miRNAs with a potential pathogenetic role in Waldenström's macroglobulinemia. Adamia S., Amin S., Patterson C., Moreau P., Minvielle S., Li C., AvetLoiseau H., Anderson K.C., Munshi N.C. and Treon S.P. Dana-Farber Cancer Institute, and Boston VA Healthcare System, Harvard Medical School, Boston, MA, USA; Hematology Department, Hopital de Nantes, Nantes, FRANCE.

5-Azacytidine inhibits the mammalian target of rapamycin complex 1 signal and induces apoptosis in Waldenström’s macroglobulinemia. Lian Xu, B. Ciccarelli, E. Hatjiharissi, S. Adamia, Y. Zhou, J. Sun, G. Yang, H. Tseng, X. Liu, Z. Hunter, L. Ioakimidis, R. Manning, C. Patterson and S.P. Treon. Bing Center for Waldenström's Macroglobulinemia, Harvard Medical School, Dana-Farber Cancer Institute, Boston, Massachusetts USA.

Role of CCL5 and Interleukin-6 in the Biology of Waldenström’s macroglobulinemia. Stephen M. Ansell, Division of Hematology, Mayo Clinic, Rochester, MN, USA.

Role of Hepatitis C In Waldenström’s macroglobulinemia. Thomas Giordano, Department of Medicine, Baylor College of Medicine, and the Houston Center for Quality of Care and Utilization Studies, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, USA.

Chronic immune stimulation and subsequent Waldenström's macroglobulinemia. Ola Landgren, Gloria Gridley, Eric A. Engels, Mary L. McMaster, Sigurdur Y. Kristinsson, Ingemar Turesson, Magnus Björkholm, Jill Koshiol. National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA; Department of Medicine, Karolinska Institutet, Hematology Center, Karolinska University Hospital, Stockholm, SWEDEN;  Department of Medicine, Section of Hematology, Malmo University Hospital, Malmo, SWEDEN.

Stockholm 2008 (IWWM-5)

The 5th International Workshop on WM (IWWM-5) was made possible through the kind and generous unrestricted grants or gifts from the following sponsors:

Peter and Helen Bing Fund for Waldenström's Macroglobulinemia

 

Karen Lee Sobol Foundation

 

Bailey family Foundation for Waldenström's Macroglobulinemia

 

Linda and Edward Nelson Fund for Waldenström's Macroglobulinemia